Products & Outsourced Services


EUGENEX Biotechnologies is a privately owned and independent dynamic research and service company engaged in innovative technologies for the production of heterologous proteins. The choice of an expression system is fundamental for optimized production and regulatory registration of the process and product. The Eugenex System consists of Mammalian Host Cell Lines growing in Animal Component Free medium, high level expression vectors and chemically defined, animal component free medium. Even as Eugenex is routinely engaged in the development of Biosimilars, they are also involved in co-development of new biopharmaceutical drugs. Eugenex offers development and consulting of the whole process, from the gene of interest to the product in consideration.
  • Adalimumab
  • Tocilizumab
  • Bevacizumab
  • Trastuzumab
  • Adalimumab
  • Denosumab
  • Infliximab
  • Natalizumab
  • Nivolumab
  • Prembolizumab